Clinical Follow-up to Evaluate the Clinical Usefulness of Gentamicin-coated Titanium Nails in Tibia Fractures

February 25, 2015 updated by: Synthes GmbH

Prospective Open Label Post Market Clinical Follow-up to Evaluate the Clinical Usefulness of the Operative Stabilization of Closed and Open Fractures of the Tibia Using Gentamicin - Coated Titanium Nails

This post market clinical follow-up is to confirm the clinical usefulness of the Expert Tibial Nail (ETN) PROtect device for operative stabilization in patients with a tibia fracture as measured by the quality of life (EQ5D, SF-12) instruments, disease-specific questionnaires (Iowa Ankle Score, WOMAC) and assessment of (Non-)Device Related Adverse Events or complications.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Berlin, Germany, 10117
        • Charite - Universitatsmedizin Berlin
      • Freiburg, Germany, 79106
        • Universitätsklinikum Freiburg
      • Heidelberg, Germany, 69120
        • Universitatsklinikum Heidelberg
      • Münster, Germany, 48149
        • University Hospital of Münster

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients presenting to the ER with a tibia fracture

Description

Inclusion Criteria:

  • Adult patients aged 18 years or more
  • Open or closed tibia fracture according to the surgical technique

Exclusion Criteria:

  • Women who are pregnant or breast-feeding or are planning to become pregnant during the study
  • Patients with consumptive/ malignant primary disease and a life expectancy of < 3 months
  • Patients with a known allergy to aminoglycosides
  • Physical or mental incapacity, which makes it impossible to obtain informed consent
  • History of drug and alcohol abuse
  • Patient unlikely to cooperate
  • Legal incompetence

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
ETN PROtect
There is only 1 cohort in this case series
Expert Tibial Nail PROtect with Gentamicin coating

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of Life: SF-12 Physical Component Summary (PCS)
Time Frame: 3, 6, 12 and 18 months post-operatively

The Short Form (SF)-12 health survey comprises 12 questions related to health and wellbeing over the prior four weeks. The responses to these 12 questions are entered into a standardized algorithm to provide summaries of physical and mental health (i.e., physical composite score [PCS] and mental composite score [MCS]). The summary scores are standardized and normalized such that a score of 50 for either the PCS or MCS corresponds to that of an average, healthy person. A score lower than 50 indicates poorer physical and mental health compared to an average, healthy person.

It was administered at 3, 6, 12 and 18 months post-operatively.

3, 6, 12 and 18 months post-operatively
Quality of Life: SF-12 Mental Component Summary (MCS)
Time Frame: 3, 6, 12 and 18 months post-operatively

The SF-12 short form health survey comprises 12 questions related to health and wellbeing over the prior four weeks. The responses to these 12 questions are entered into a standardized algorithm to provide summaries of physical and mental health (i.e., physical composite score [PCS] and mental composite score [MCS]). The summary scores are standardized and normalized such that a score of 50 for either the PCS or MCS corresponds to that of an average, healthy person. A score lower than 50 indicates poorer physical and mental health compared to an average, healthy person.

It was administered at 3, 6, 12 and 18 months post-operatively.

3, 6, 12 and 18 months post-operatively
Quality of Life: EQ-5D
Time Frame: 3, 6, 12 and 18 months post-operatively
The Euroqol Health Survey (EQ-5D, 3-level) was completed on five dimensions (mobility, self care, usual activities, pain/discomfort and anxiety/depression) to measure health-related quality of life on a scale from 0-1. A higher score indicates better quality of life.
3, 6, 12 and 18 months post-operatively
Functional Outcome: IOWA Ankle Score
Time Frame: Baseline, 3, 6, 12 and 18 months post-operatively
The Iowa Ankle Score was administered at baseline (retrospective assessment of pre-trauma condition) as well as at 3, 6, 12 and 18 months post-operatively to measures ankle function across four dimensions (function, freedom from pain, gait, range of motion) on a scale of 0-100, where 100 is assigned to full function.
Baseline, 3, 6, 12 and 18 months post-operatively
Functional Outcome: WOMAC
Time Frame: 3, 6, 12 and 18 months post-operatively

The Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire was administered at 3, 6, 12 and 18 months post-operatively to assess three dimensions: pain, disability and joint stiffness in the knee.

Each question is scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores are summed up, with a possible score range of 0-96. A higher score on the WOMAC indicate more functional limitations.

3, 6, 12 and 18 months post-operatively
Infection Adverse Events
Time Frame: 0 - 18 months

Infections at the site of ETN PROtect implantation were classified according to Center for Disease Control (CDC) definition into:

  • superficial incisional surgical site infection (SSI), affecting skin and subcutaneous tissue
  • deep incisional SSI, affecting deep soft tissue
  • organ/ space SSI (Osteomyelitis), affecting joint or bursa
0 - 18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evidence of Anatomic Bone Union According to Johnson Classification
Time Frame: 12 months

Anatomic bone union was assessed according to Johnson et al.*:

A0: pseudoarthrosis; A1: unilateral pseudoarthrosis; A2: insufficient unilateral bone mass; A3: contiguous union without hypertrophy; A4: solid union of the fracture site.

*Johnson EE, Urist MR, Finerman GA. Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein. A preliminary report. Clin.Orthop.Relat Res. 1988;249-57

12 months
Evidence of Economic Bone Union According to Johnson Classification
Time Frame: 12 months

Economic bone union was assessed according to Johnson et al.*:

E0: complete invalid; E1: no gainful employment; E2: able to work but did not return to previous occupation; E3: returned to previous occupation on a part-time or limited status; E4: returned to previous occupation without restrictions.

*Johnson EE, Urist MR, Finerman GA. Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein. A preliminary report. Clin.Orthop.Relat Res. 1988;249-57

12 months
Evidence of Functional Bone Union According to Johnson Classification
Time Frame: 12 months

Functional bone union was assessed according to Johnson et al.*:

F0: motion at the fracture site; F1: level of pain is the same as before operation but able to perform all daily tasks of living; F2: occasional extremity pain and able to perform activities of daily living; F3: no pain and able to perform all activities except sports; F4: complete recovery, no recurrent episodes of pain, and unrestricted activity.

*Johnson EE, Urist MR, Finerman GA. Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein. A preliminary report. Clin.Orthop.Relat Res. 1988;249-57

12 months
Surgeon's Perceived Satisfaction
Time Frame: 6 weeks, 3 and 6 months post-operatively
Surgeons' perceived satisfaction was assessed on a scale from 0 to 100 (0 = very satisfied, 100 = disappointed).
6 weeks, 3 and 6 months post-operatively
Likelihood to Develop Wound Infection Assessed by Surgeon
Time Frame: 6 weeks, 3 and 6 months post-operatively
The likelihood to develop a wound infection was assessed by the surgeon on a scale from 0 to 100 (0 = almost nil, 100 = absolutely sure).
6 weeks, 3 and 6 months post-operatively
Likelihood to Develop a Non-union Assessed by Surgeon
Time Frame: 6 weeks, 3 and 6 months post-operatively
The likelihood to develop a non-union was assessed by the surgeon on a scale from 0 to 100 (0 = almost nil, 100 = absolutely sure).
6 weeks, 3 and 6 months post-operatively
Pain by Visual Analog Scale (VAS)
Time Frame: 6 weeks, 3, 6, 12 and 18 months post-operatively
Leg pain intensity was rated on a 100-mm visual analog scale (VAS). A score of zero indicated no pain at all, and 100 represented the worst possible pain.
6 weeks, 3, 6, 12 and 18 months post-operatively
Patient's Perceived Satisfaction
Time Frame: 6 months
Patient's perceived satisfaction was scored on a 100mm visual analog scale (VAS). A score of zero indicated no satisfaction, while a score of 100 indicated completely satisfied.
6 months
Time to Full Weight Bearing
Time Frame: 0 - 18 months
The time from surgery to full weight bearing was assessed in days.
0 - 18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Michael J. Raschke, MD, University Hospital of Münster, Germany

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2011

Primary Completion (Actual)

October 1, 2013

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

January 21, 2011

First Submitted That Met QC Criteria

January 21, 2011

First Posted (Estimate)

January 24, 2011

Study Record Updates

Last Update Posted (Estimate)

March 17, 2015

Last Update Submitted That Met QC Criteria

February 25, 2015

Last Verified

February 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • STU-BIO-T-XX-190-02

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tibia Fractures

Clinical Trials on ETN PROtect

Subscribe